Affibody
Sweden - SolnaBiotechnology
Focus: Affibody is a Swedish biotechnology company specializing in antibody mimetics, a novel protein engineering platform for developing therapeutics across oncology, immunology, ophthalmology, dermatology, and neurology. The company operates as a focused pipeline-stage biotech with early-to-mid-stage clinical programs.
Profile data last refreshed 16m ago · AI intelligence enriched 2w ago
Open Jobs
0
About Affibody
AI assessmentNot HiringNo open roles listed right now. Follow Affibody to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Affibody's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ABY-271
Metastatic Breast CancerClinical Trials (1)
NCT07081555A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer
Phase 1Help build intelligence for Affibody
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.